Developer docs
API playgroundTry for free, no card

Search company profiles

Xyphos Biosciences

Full company profile

uuid000bfl3

Namestring
Xyphos Biosciences
Legal namestring
Xyphos Biosciences, Inc.
Websiteurl
xyphosinc.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Xyphos Biosciences is a clinical-stage biotechnology company developing a proprietary convertibleCAR™ cell therapy platform for treating cancer, with a stated focus on relapsed hematological malignancies and solid tumors. The company's core technology modifies the natural NKG2D receptor on immune cells — including natural killer cells and T-cells — to enable controllable targeting of tumor antigens via engineered bispecific antibodies. Its complementary ACCEL™ (Advanced Cellular Control through Engineered Ligands) platform allows functional molecules such as bispecific antibodies to be attached to immune cells, providing the ability to engineer and re-engineer therapies inside the body to address tumor antigens that change to evade detection. Headquartered in South San Francisco, California, Xyphos holds registered trademarks for both the convertibleCAR™ and ACCEL™ brands and operates an R&D site led by a PhD-level management team with experience across Merck Research Labs, Pfizer, Novartis, Adicet Bio, and Agensys/Astellas.

Xyphos operates as a wholly owned subsidiary of Astellas Pharma (TYO: 4503) and functions as Astellas' Cancer Cell Therapy division. Its commercial model is not product sales but research collaboration and licensing. The most significant commercial event is the May 2024 research collaboration and license agreement with Poseida Therapeutics, under which Poseida receives a $50 million upfront payment, up to $550 million in development and sales milestones, and low double-digit tiered royalties on net sales, in exchange for combining Poseida's allogeneic CAR-T platform with Xyphos' ACCEL technology to develop convertibleCAR programs targeting solid-tumor cancers. Concurrently, Astellas invested $50 million in Poseida ($25 million for shares and $25 million for exclusive negotiation rights on Poseida's P-MUC1C-ALLO1 program), securing a board observer seat. Beyond the Poseida arrangement, Xyphos generates no disclosed product revenue; pricing is not publicly disclosed as the company is pre-commercial.

The company is pre-commercial and currently pre-revenue, with go-to-market executed via enterprise licensing and OEM-style partnerships rather than traditional biopharma distribution. Its customer base consists of biopharmaceutical partners (Poseida being the single named external counterparty) plus its parent Astellas, which provides internal R&D funding. Marketing is limited to a corporate website, LinkedIn presence via Astellas, and educational video content. Founded in 2017, Xyphos is a privately held Delaware/California corporation with a small core employee base (1-10 per firmographic data) supplemented by senior directors and a dedicated leadership team.

Short descriptiontext

Xyphos Biosciences is a pre-commercial biotech subsidiary of Astellas Pharma developing a proprietary convertibleCAR™ cell therapy platform that modifies the NKG2D receptor to enable controllable immune cell targeting of solid-tumor and hematological cancer antigens.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CAR-T cell therapy, cell therapy platform, immuno-oncology research, cancer immunotherapy, bispecific antibody technology
Industry3 codes
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Research Collaboration and Licensing
TypeLicensing Royalties
Description

Xyphos generates revenue through research collaborations and licensing agreements with pharmaceutical partners. Under the Poseida partnership, the company receives upfront payments ($50M), potential development and sales milestones (up to $550M), and tiered royalties on net sales (low double-digit percentages).

biopharminternational.com
2Technology Investment Returns
TypeSubscription Recurring
Description

As a subsidiary of Astellas Pharma, revenue is generated through internal technology transfer and development funding from the parent company, supporting advancement of the cancer cell therapy platform through clinical development.

biopharminternational.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1convertibleCAR
Description

Proprietary convertibleCAR (Chimeric Antigen Receptor) technology that creates flexible cell therapies engineered to target multiple tumor antigens by utilizing a modified NKG2D receptor.

xyphosinc.com
+1 more record
Core offering1 text field

Xyphos Biosciences develops a flexible and controllable immune cell therapy platform for cancer treatment using its proprietary convertibleCAR™ and ACCEL™ technologies. The platform modifies the natural NKG2D receptor on natural killer cells and T-cells to enable controllable targeting of tumor cells through engineered bispecific antibodies that can be adapted to recognize single or multiple tumor antigens. The technology is offered through research collaborations and licensing agreements with pharmaceutical partners for co-development and commercialization of cell therapy programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Potential to target multiple tumor antigens with a single therapy platform
Product overview1 text field

Xyphos Biosciences is developing a flexible and controllable immune cell therapy platform for cancer treatment. Their core technology is the convertibleCAR™ platform, which utilizes ACCEL™ (Advanced Cellular Control through Engineered Ligands) technology to create cell therapies that can be engineered and re-engineered inside the body to target single or multiple tumor antigens. The platform modifies the NKG2D receptor on immune cells and uses engineered molecules (bispecific antibodies) to enable specific tumor targeting while avoiding immune rejection. Xyphos operates as a wholly owned subsidiary of Astellas Pharma, serving as Astellas' Cancer Cell Therapy center.

Product and service3 records
1convertibleCAR™ Platform
CategoryCell therapy platform / Immuno-oncology technology
Description

Proprietary chimeric antigen receptor (CAR) platform that modifies the natural NKG2D receptor on natural killer cells and T-cells to enable controllable targeting of tumor cells. The platform uses engineered bispecific antibodies to redirect immune cell specificity, allowing the therapy to be engineered and re-engineered inside the body to target single or multiple tumor antigens and adapt as tumors evolve to evade detection. Offered to biopharmaceutical partners for co-development and commercialization of cell therapy programs.

2ACCEL™ (Advanced Cellular Control through Engineered Ligands) Technology
CategoryCell therapy platform / Immuno-oncology technology
Description

Technology platform enabling attachment of various functional molecules, including bispecific antibodies, to engineered immune cells to redirect their targeting. ACCEL provides greater speed and flexibility than currently approved CAR-T therapies and supports off-the-shelf, Standard Pharmaceutical-like Cell Therapy applications for solid-tumor and hematological cancer programs.

3Research Collaboration and Licensing of convertibleCAR Programs
CategoryLicensing and research collaboration services
Description

B2B research collaboration and licensing offering in which Xyphos grants biopharmaceutical partners access to its convertibleCAR and ACCEL technologies for the co-development and commercialization of cell therapy programs, with revenue from upfront payments, development and sales milestones, and tiered royalties on net sales.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-01
Description

Astellas Pharma's wholly owned subsidiary Xyphos Biosciences entered into a research collaboration and license agreement with Poseida Therapeutics to develop convertibleCAR programs targeting solid-tumor cancers. The collaboration combines Poseida's allogeneic CAR-T platform with Xyphos' ACCEL technology. Poseida receives $50 million upfront payment plus potential development and sales milestones and contingency payments totaling up to $550 million, as well as low double-digit tiered royalties on net sales. Additionally, Astellas is investing $50 million total in Poseida, comprising $25 million to acquire shares and a $25 million payment for exclusive negotiation rights on Poseida's clinical-stage P-MUC1C-ALLO1 program, with Astellas gaining a board observer seat.

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage allogeneic CAR-T developer using TALEN gene editing. Comparable to Xyphos in targeting solid tumors with engineered allogeneic platforms, though at earlier commercial stage.

TypeDirect peer
Description

Develops gamma delta T cell therapies for cancer with off-the-shelf, allogeneic platform. Leadership includes Xyphos' Daulet Satpayev (formerly VP Research at Adicet). Directly comparable in adaptive immune cell therapy for solid tumors.

TypeDirect peer
Description

iPSC-derived allogeneic cell therapy platform for oncology. Comparable to Xyphos in pursuing engineered, off-the-shelf immune cell approaches with potential for multiplexed targeting.

TypeDirect peer
Description

Develops iPSC-derived NK cell and T-cell therapies for cancer, with an off-the-shelf, multiplexed platform directly comparable to Xyphos' NK cell-based convertibleCAR approach. Both target solid tumors and hematologic malignancies with engineered immune cells.

TypeBroad incumbent
Description

Gene-edited cell therapy leader with approved Casgevy and a broad pipeline. Comparable to Xyphos in next-gen cell therapy platforms but operates at a much larger scale with diversified technology assets.

TypeDirect peer
Description

Allogeneic CAR-T and CAR-NK developer using CRISPR gene editing for next-gen cell therapies. Directly comparable to Xyphos in applying engineered immune cell approaches to overcome tumor resistance.

TypeDirect peer
Description

Allogeneic CAR-T platform developer and Xyphos' primary collaboration partner. Poseida's P-MUC1C-ALLO1 program combines with Xyphos' ACCEL technology, making it the most directly comparable peer in next-gen cell therapy for solid tumors.

TypeDirect peer
Description

Pure-play NK cell therapy developer using engineered CAR-NK platforms for solid tumors and hematologic malignancies. Highly comparable to Xyphos' NK cell-based convertibleCAR platform in modality, target indications, and adaptive targeting strategies.

TypeDirect peer
Description

Leading allogeneic CAR-T developer with multiple clinical-stage programs. Comparable to Xyphos as a next-generation off-the-shelf cell therapy platform targeting both hematologic malignancies and solid tumors.

TypeBroad incumbent
Description

Commercial CAR-T leader via Kite (Yescarta, Tecartus) and broader immuno-oncology portfolio. Sets the competitive standard for cell therapy commercialization against which Xyphos' next-gen platform must compete.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Xyphos Biosciences

Cell Therapyxyphosinc.com

Xyphos Biosciences is a pre-commercial biotech subsidiary of Astellas Pharma developing a proprietary convertibleCAR™ cell therapy platform that modifies the NKG2D receptor to enable controllable immune cell targeting of solid-tumor and hematological cancer antigens.

What Xyphos Biosciences does

Xyphos Biosciences is a clinical-stage biotechnology company developing a proprietary convertibleCAR™ cell therapy platform for treating cancer, with a stated focus on relapsed hematological malignancies and solid tumors. The company's core technology modifies the natural NKG2D receptor on immune cells — including natural killer cells and T-cells — to enable controllable targeting of tumor antigens via engineered bispecific antibodies. Its complementary ACCEL™ (Advanced Cellular Control through Engineered Ligands) platform allows functional molecules such as bispecific antibodies to be attached to immune cells, providing the ability to engineer and re-engineer therapies inside the body to address tumor antigens that change to evade detection. Headquartered in South San Francisco, California, Xyphos holds registered trademarks for both the convertibleCAR™ and ACCEL™ brands and operates an R&D site led by a PhD-level management team with experience across Merck Research Labs, Pfizer, Novartis, Adicet Bio, and Agensys/Astellas.

Xyphos operates as a wholly owned subsidiary of Astellas Pharma (TYO: 4503) and functions as Astellas' Cancer Cell Therapy division. Its commercial model is not product sales but research collaboration and licensing. The most significant commercial event is the May 2024 research collaboration and license agreement with Poseida Therapeutics, under which Poseida receives a $50 million upfront payment, up to $550 million in development and sales milestones, and low double-digit tiered royalties on net sales, in exchange for combining Poseida's allogeneic CAR-T platform with Xyphos' ACCEL technology to develop convertibleCAR programs targeting solid-tumor cancers. Concurrently, Astellas invested $50 million in Poseida ($25 million for shares and $25 million for exclusive negotiation rights on Poseida's P-MUC1C-ALLO1 program), securing a board observer seat. Beyond the Poseida arrangement, Xyphos generates no disclosed product revenue; pricing is not publicly disclosed as the company is pre-commercial.

The company is pre-commercial and currently pre-revenue, with go-to-market executed via enterprise licensing and OEM-style partnerships rather than traditional biopharma distribution. Its customer base consists of biopharmaceutical partners (Poseida being the single named external counterparty) plus its parent Astellas, which provides internal R&D funding. Marketing is limited to a corporate website, LinkedIn presence via Astellas, and educational video content. Founded in 2017, Xyphos is a privately held Delaware/California corporation with a small core employee base (1-10 per firmographic data) supplemented by senior directors and a dedicated leadership team.

Xyphos Biosciences firmographics

Firmographics
Name
Xyphos Biosciences
Legal name
Xyphos Biosciences, Inc.
Website
https://xyphosinc.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Xyphos Biosciences is a pre-commercial biotech subsidiary of Astellas Pharma developing a proprietary convertibleCAR™ cell therapy platform that modifies the NKG2D receptor to enable controllable immune cell targeting of solid-tumor and hematological cancer antigens.
Ownership category
akta.pro rank

Xyphos Biosciences industry classification

Industry
Product category
Cell Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)

Keywords

  • CAR-T cell therapy
  • Cell therapy platform
  • Immuno-oncology research
  • Cancer immunotherapy
  • Bispecific antibody technology

Where Xyphos Biosciences is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Xyphos Biosciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Research Collaboration and Licensing: Xyphos generates revenue through research collaborations and licensing agreements with pharmaceutical partners. Under the Poseida partnership, the company receives upfront payments ($50M), potential development and sales milestones (up to $550M), and tiered royalties on net sales (low double-digit percentages).
  2. Technology Investment Returns: As a subsidiary of Astellas Pharma, revenue is generated through internal technology transfer and development funding from the parent company, supporting advancement of the cancer cell therapy platform through clinical development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Xyphos Biosciences product offering

Product offering

Core offering

Xyphos Biosciences develops a flexible and controllable immune cell therapy platform for cancer treatment using its proprietary convertibleCAR™ and ACCEL™ technologies. The platform modifies the natural NKG2D receptor on natural killer cells and T-cells to enable controllable targeting of tumor cells through engineered bispecific antibodies that can be adapted to recognize single or multiple tumor antigens. The technology is offered through research collaborations and licensing agreements with pharmaceutical partners for co-development and commercialization of cell therapy programs.

Product overview

Xyphos Biosciences is developing a flexible and controllable immune cell therapy platform for cancer treatment. Their core technology is the convertibleCAR™ platform, which utilizes ACCEL™ (Advanced Cellular Control through Engineered Ligands) technology to create cell therapies that can be engineered and re-engineered inside the body to target single or multiple tumor antigens. The platform modifies the NKG2D receptor on immune cells and uses engineered molecules (bispecific antibodies) to enable specific tumor targeting while avoiding immune rejection. Xyphos operates as a wholly owned subsidiary of Astellas Pharma, serving as Astellas' Cancer Cell Therapy center.

Differentiator

Problem solved

Functional benefit

Brands

  • convertibleCAR: Proprietary convertibleCAR (Chimeric Antigen Receptor) technology that creates flexible cell therapies engineered to target multiple tumor antigens by utilizing a modified NKG2D receptor.
  • ACCEL Technology

Products and services

  • convertibleCAR™ Platform Proprietary chimeric antigen receptor (CAR) platform that modifies the natural NKG2D receptor on natural killer cells and T-cells to enable controllable targeting of tumor cells. The platform uses engineered bispecific antibodies to redirect immune cell specificity, allowing the therapy to be engineered and re-engineered inside the body to target single or multiple tumor antigens and adapt as tumors evolve to evade detection. Offered to biopharmaceutical partners for co-development and commercialization of cell therapy programs.
  • ACCEL™ (Advanced Cellular Control through Engineered Ligands) Technology Technology platform enabling attachment of various functional molecules, including bispecific antibodies, to engineered immune cells to redirect their targeting. ACCEL provides greater speed and flexibility than currently approved CAR-T therapies and supports off-the-shelf, Standard Pharmaceutical-like Cell Therapy applications for solid-tumor and hematological cancer programs.
  • Research Collaboration and Licensing of convertibleCAR Programs B2B research collaboration and licensing offering in which Xyphos grants biopharmaceutical partners access to its convertibleCAR and ACCEL technologies for the co-development and commercialization of cell therapy programs, with revenue from upfront payments, development and sales milestones, and tiered royalties on net sales.

Quantifiable outcome

  • Potential to target multiple tumor antigens with a single therapy platform

Companies that use Xyphos Biosciences

Customer profile

Segments1 record

Ideal customer profiles2 records

Xyphos Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Xyphos Biosciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Poseida TherapeuticscoreStrategic or Co-development Partner · 1 May 2024Astellas Pharma's wholly owned subsidiary Xyphos Biosciences entered into a research collaboration and license agreement with Poseida Therapeutics to develop convertibleCAR programs targeting solid-tumor cancers. The collaboration combines Poseida's allogeneic CAR-T platform with Xyphos' ACCEL technology. Poseida receives $50 million upfront payment plus potential development and sales milestones and contingency payments totaling up to $550 million, as well as low double-digit tiered royalties on net sales. Additionally, Astellas is investing $50 million total in Poseida, comprising $25 million to acquire shares and a $25 million payment for exclusive negotiation rights on Poseida's clinical-stage P-MUC1C-ALLO1 program, with Astellas gaining a board observer seat.

Scale indicators3 records

Recent moves1 record

Expansion highlights5 records

Xyphos Biosciences competitors and assessment

Company assessment

Emerging players

  • Cellectis: Clinical-stage allogeneic CAR-T developer using TALEN gene editing. Comparable to Xyphos in targeting solid tumors with engineered allogeneic platforms, though at earlier commercial stage.

Direct peers

  • Adicet Bio: Develops gamma delta T cell therapies for cancer with off-the-shelf, allogeneic platform. Leadership includes Xyphos' Daulet Satpayev (formerly VP Research at Adicet). Directly comparable in adaptive immune cell therapy for solid tumors.
  • Century Therapeutics: iPSC-derived allogeneic cell therapy platform for oncology. Comparable to Xyphos in pursuing engineered, off-the-shelf immune cell approaches with potential for multiplexed targeting.
  • Fate Therapeutics: Develops iPSC-derived NK cell and T-cell therapies for cancer, with an off-the-shelf, multiplexed platform directly comparable to Xyphos' NK cell-based convertibleCAR approach. Both target solid tumors and hematologic malignancies with engineered immune cells.
  • Caribou Biosciences: Allogeneic CAR-T and CAR-NK developer using CRISPR gene editing for next-gen cell therapies. Directly comparable to Xyphos in applying engineered immune cell approaches to overcome tumor resistance.
  • Poseida Therapeutics: Allogeneic CAR-T platform developer and Xyphos' primary collaboration partner. Poseida's P-MUC1C-ALLO1 program combines with Xyphos' ACCEL technology, making it the most directly comparable peer in next-gen cell therapy for solid tumors.
  • Nkarta Therapeutics: Pure-play NK cell therapy developer using engineered CAR-NK platforms for solid tumors and hematologic malignancies. Highly comparable to Xyphos' NK cell-based convertibleCAR platform in modality, target indications, and adaptive targeting strategies.
  • Allogene Therapeutics: Leading allogeneic CAR-T developer with multiple clinical-stage programs. Comparable to Xyphos as a next-generation off-the-shelf cell therapy platform targeting both hematologic malignancies and solid tumors.

Broad incumbents

  • CRISPR Therapeutics: Gene-edited cell therapy leader with approved Casgevy and a broad pipeline. Comparable to Xyphos in next-gen cell therapy platforms but operates at a much larger scale with diversified technology assets.
  • Gilead Sciences (Kite Pharma): Commercial CAR-T leader via Kite (Yescarta, Tecartus) and broader immuno-oncology portfolio. Sets the competitive standard for cell therapy commercialization against which Xyphos' next-gen platform must compete.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Xyphos Biosciences social profiles

Digital presence

Xyphos Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Xyphos Biosciences leadership team

Management profile

Number of profiles

Profiles7 records

Xyphos Biosciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Xyphos Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xyphos Biosciences

What does Xyphos Biosciences do?

Xyphos Biosciences develops a flexible and controllable immune cell therapy platform for cancer treatment using its proprietary convertibleCAR™ and ACCEL™ technologies. The platform modifies the natural NKG2D receptor on natural killer cells and T-cells to enable controllable targeting of tumor cells through engineered bispecific antibodies that can be adapted to recognize single or multiple tumor antigens. The technology is offered through research collaborations and licensing agreements with pharmaceutical partners for co-development and commercialization of cell therapy programs.

Is Xyphos Biosciences a public or private company?

Xyphos Biosciences is a private company. It is classified as corporate owned and is currently operating.

When was Xyphos Biosciences founded?

Xyphos Biosciences was founded in 2017. It employs 1 to 10 people.

Where is Xyphos Biosciences based?

Xyphos Biosciences is headquartered in South San Francisco, United States, in the North America region.

How does Xyphos Biosciences make money?

Two revenue lines are on record. Research Collaboration and Licensing is the primary driver. The others are technology Investment Returns.

Who are Xyphos Biosciences's main competitors?

Cellectis is listed as an emerging player. Direct peers are Adicet Bio, Century Therapeutics, Fate Therapeutics, Caribou Biosciences, Poseida Therapeutics, Nkarta Therapeutics and Allogene Therapeutics. Broad incumbents are CRISPR Therapeutics and Gilead Sciences (Kite Pharma).

Does Xyphos Biosciences have an API?

No public API is recorded for Xyphos Biosciences.

What industry is Xyphos Biosciences in?

Xyphos Biosciences's product category is Cell Therapy. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAABAD, NK Cell Therapies. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerPoseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos BiosciencesPoseida Therapeutics shares rose 18% to $2.86 after announcing a research collaboration and license agreement with Xyphos Biosciences. The deal combines Poseida's allogeneic CAR-T platform with Xyphos' Accel technology to target solid tumors, with Xyphos reimbursing costs and handling development and commercialization. Poseida will receive $50 million upfront plus potential milestones and contingency payments up to $550 million.NasdaqAstellas, Poseida Collaborate To Develop Novel Allogeneic Cell Therapies In OncologyAstellas' Xyphos Biosciences and Poseida Therapeutics signed a research and license agreement to develop convertible CAR-T therapies. Poseida will receive $50 million upfront plus up to $550 million in milestones and royalties. Xyphos will handle development and commercialization.ForbesSynthetic Biology Startup Acquires AI Platform To Disrupt The Drug IndustrySynthetic biology company AbSci has acquired AI platform Denovium to integrate artificial intelligence into its drug discovery and manufacturing workflows. This strategic move aims to accelerate the development of therapeutics by optimizing cell-line selection, building on AbSci's recent $65 million Series E funding. The company also announced an ongoing partnership with Astellas and Xyphos to identify optimal cell-lines for immuno-oncology treatments.BioSpacePHANES THERAPEUTICS entered into a research collaboration with Xyphos Biosciences, Inc., an Astellas CompanyPhanes Therapeutics entered a research collaboration with Xyphos Biosciences, an Astellas Company, to evaluate cell therapies in oncology using its PACbody and SPECpair platforms. Phanes will receive a technology access payment and further research support, with financial terms undisclosed. The company's lead molecule has entered Phase 1 clinical study.PR NewswireAbSci Enters Biologics Development Collaboration with Xyphos Biosciences, an Astellas CompanyAbSci announced a collaboration with Xyphos Biosciences, an Astellas company, to screen and identify a variant of Xyphos' MicAbody lead candidate for manufacturing cell line development. The agreement calls for AbSci to use its Protein Printing technology and a custom E. coli SoluPro production strain. Financial terms were not disclosed.ReutersAstellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 millionAstellas Pharma acquired U.S. biotech Xyphos Biosciences for up to $665 million, paying $120 million upfront with milestone payments. The deal expands Astellas' immuno-oncology, and the company also agreed to buy Audentes Therapeutics for about $3 billion, due to close in January.PR NewswireAstellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.Astellas acquired Xyphos Biosciences, gaining its ACCEL immuno-oncology platform and NKG2D-based CAR technology. The deal paid $120 million upfront, with a total transaction value of $665 million, and Xyphos's first convertibleCAR-T candidate is scheduled for a first-in-human study in 2021.PR NewswireKey Patent Issued for Xyphos Biosciences' ACCEL™ Technology PlatformXyphos Biosciences Inc. announced the issuance of U.S. Patent No. 10,259,858 covering its ACCEL technology platform, which enables the programming of a patient's immune cells to attack tumor cells with greater specificity and potentially lower toxicity compared to existing cell therapies. The patent includes broad composition-of-matter claims for the company's cell therapy products, including its convertibleCAR-T cell technology that exploits the NKG2D immune surveillance pathway. Xyphos is a privately held development-stage biotechnology company headquartered in South San Francisco, with its first convertibleCAR-T cell product candidate in preclinical development and scheduled for a first-in-human clinical study in 2021.PR NewswireThe Parker Institute for Cancer Immunotherapy Partners with Xyphos Biosciences to Develop Universal Programmable CAR-T Cells for Cancer TreatmentThe Parker Institute for Cancer Immunotherapy and Xyphos Biosciences announced a collaboration to develop universal CAR-T therapies for multiple cancer types using Xyphos' convertibleCAR platform. The partnership aims to address limitations of first-generation approved cell therapies, including relapse and lack of efficacy against solid tumors, by enabling more controlled antigen recognition and the ability to switch CAR-T cells on and off. Xyphos' ACCEL technology uses engineered NKG2D receptors that remain inactive until activated by proprietary bispecific antibodies, allowing a single CAR-T therapy to be precisely targeted to any antigen-expressing cell.